NKTR and cancer: Several current products include ALT-803 ALT-803 (Hu et al., 2018), P22339 (Hu et al., 2018), chimeric IL-15 apolipoprotein A-I (Ochoa et al., 2018), or NKTR-255 (Miyazaki et al., 2021), illustrating the promise of IL-15 in cancer therapy.